Reading Wegovy blogs: how to sort useful information from noise

Why Wegovy blogs exist, and what they're actually good for

There's a simple reason thousands of Wegovy blogs have appeared since the medicine launched in the UK: people want to know what the experience is like before they commit to anything. That's a reasonable instinct. Reading about someone else's first injection, their nausea in week two, or the point at which their appetite visibly changed is a form of preparation that clinical leaflets don't always offer.

Where blogs genuinely help is in normalising the adjustment period. Many readers arrive expecting dramatic results from week one, and personal accounts help calibrate that. Someone describing mild nausea after a dose increase, which then settled, is more reassuring than a list of percentage side-effect rates. The lived texture is real and valuable.

The problem starts when a blog's personal outcome gets read as a prediction. One person's 18% weight loss over 68 weeks at 2.4mg tells you something meaningful about that person's experience. It doesn't tell you what will happen in your case, with your medical history, at whatever dose a prescriber decides is appropriate. A question our prescribers hear most weeks is some version of: 'I read on a blog that you get really bad nausea, is that going to happen to me?' The honest answer is: maybe for a few days, maybe not at all, and almost certainly not in the way the blogger described it.

Use blogs for texture and questions to bring to your consultation. Don't use them for dosing expectations, eligibility assumptions, or reassurance that a medicine is right for you.

What blogs often get wrong about Wegovy's clinical evidence

The trial data for semaglutide is solid and worth knowing accurately. In the STEP 1 trial (68 weeks, published in the New England Journal of Medicine) participants using semaglutide 2.4mg weekly alongside lifestyle changes achieved an average body-weight reduction of around 15%. That's the figure. Not 20%, not 'up to 30%', and not the figure from a different medicine's trial.

Blogs frequently conflate Wegovy with tirzepatide (Mounjaro), or quote figures from the newer 7.2mg semaglutide dose, or from the oral Wegovy tablet, each of which is a distinct product with its own data. The 7.2mg weekly injection, approved by the MHRA in January 2026, showed average weight loss of around 20.7% over 72 weeks in trials. That's meaningfully different from the 2.4mg figure, and a blog that presents them interchangeably is muddying the picture.

If you want the actual prescribing information (what doses exist, what the contraindications are, how the titration schedule works) the most reliable starting point is the NHS medicines page for semaglutide. It's written for patients, it's regularly updated, and it doesn't have anything to sell you.

NICE has also evaluated semaglutide for weight management under guidance TA875. The recommendation comes with conditions: treatment within a specialist weight management service, a maximum of two years, and minimum eligibility thresholds. Blogs rarely mention any of that context.

Eligibility: what blogs skip over

Personal blogs almost never discuss eligibility in any detail, because the author already qualified. For a reader who doesn't know whether they're a candidate, that's a significant gap.

The UK licence for Wegovy covers adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related health condition, things like high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes. BMI thresholds are adjusted downward by 2.5 kg/m² for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. Hitting the BMI number is the start of the conversation, not the end of it: a prescriber looks at the whole clinical picture before approving treatment.

You can explore how Wegovy works and who it's licensed for on our treatment overview page, and check eligibility more broadly on our weight-loss treatment options page. There's also a broader overview of what semaglutide is and how it's used if you want the mechanism explained clearly.

One thing worth knowing before reading any blog: Wegovy is available on the NHS only through specialist weight management services, and waiting lists are commonly long. Private prescription through a regulated online pharmacy is the alternative route, but that, too, requires a clinical assessment. No legitimate route skips that step.

Side effects, cost, and the things blogs mention but don't fully explain

Gastrointestinal side effects (nausea, loose stools, indigestion, occasional vomiting) are the ones blogs discuss most, and they are genuinely common, especially in the early weeks and after each dose increase. Most people find they ease as the body adjusts. What blogs often miss is that the slow titration schedule exists precisely to reduce their severity: starting at 0.25mg and stepping up over several months is not impatience, it's the design of the treatment.

A less-discussed side effect that deserves more space: the MHRA highlighted acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines in a Drug Safety Update in January 2026, and if you have seen questions about Wegovy and bloating, that page explains what is worth monitoring and when symptoms need urgent attention. Severe abdominal pain that radiates to the back, with or without vomiting, warrants prompt medical attention, not a Google search or a blog comment. Anyone on treatment should know this. You can report suspected side effects at the MHRA's Yellow Card service.

On cost: blogs rarely give current pricing, and when they do the figures date quickly. The private market for Wegovy has shifted considerably. For honest context on what private semaglutide treatment typically costs and what should be included in any price, our guide to buying Wegovy privately is a practical read. One thing worth knowing: if you see a price that seems far below the market, or a seller offering these medicines without requiring a proper consultation, that's a red flag, not a deal. It is also worth being aware that semaglutide is licensed for human use only, so if you have come across content about semaglutide being used in dogs or read anything about giving Wegovy to dogs, those are separate topics that have no bearing on how the medicine is prescribed or used for people.

If you're ready to find out whether you're a candidate for treatment, you can check your eligibility with our prescribers, the consultation is free, and it's reviewed by a real clinician the same day.